Doctors & patients are saying about 'A-Fib.com'...
"A-Fib.com is a great web site for patients, that is unequaled by anything else out there."
Dr. Douglas L. Packer, MD, FHRS, Mayo Clinic, Rochester, MN
"Jill and I put you and your work in our prayers every night. What you do to help people through this [A-Fib] process is really incredible."
Jill and Steve Douglas, East Troy, WI
“I really appreciate all the information on your website as it allows me to be a better informed patient and to know what questions to ask my EP.
Faye Spencer, Boise, ID, April 2017
“I think your site has helped a lot of patients.”Dr. Hugh G. Calkins, MD Johns Hopkins,
Baltimore, MD
2024 AF Symposium: A-Fib Reports About Benefits of Ablation—Part V and Summary
“The Benefits of Ablation Across the AF Spectrum: From Early Intervention to Late-Stage Heart Failure,” the Friday morning session of the 2024 Atrial Fibrillation (AF) Symposium (February 3, 2024), featured five speakers. Below is the fifth talk of this session and then my Summary of All Five Talks. (For the earlier reports, see 2024 AF Symposium My Summary Reports.)
Medications vs Catheter Ablation for Initial Treatment of AF–Guidance for the Clinician
Dr. Francis Marchlinski
Dr. Francis Marchlinski of the Un. of Pennsylvania, Philadelphia, PA, gave the fifth talk in what was described as the “most important session of the whole meeting.”
Dr. Marchlinski cited several recent studies (such as “STOP-AF“) which have led researchers to change today’s AF Guidelines. Catheter Ablation is now a first-choice option (Class 1A) for most patients. [See Excerpts from the AF Guidelines below].
In general, AF Ablation is superior to medical therapy (use of antiarrhythmic drugs) with low risk. Ablation reduces the development of persistent AF and prevents the progression of AF.
It’s a first-choice option for younger (<70) symptomatic patients with few comorbidities (other illnesses), but is also helpful to older patients …Continue reading my report> go of Dr. Marchlinski’s talk.
My Summary of All Five Talks
“If you look at the lectures [in this session], every one of them is Guideline changing This is the most important session of the whole [Symposium] meeting.”—Dr. Nassir Marrouche
“The Benefits of Ablation Across the AF Spectrum: From Early Intervention to Late-Stage Heart Failure” session featured five speakers:
• Stephan Willems, Asklepios Clinic St. Georg, Hamburg, Germany
• Jason Andrade, VCH Research Institute, University of British Columbia, Canada
• Philipp Sommer, The Heart and Diabetes Center North Rhine-Westphalia, Germany
• Douglas Packer, Intermountain Heart Institute, Murray, UT
• Francis Marchlinski of the Un. of Pennsylvania, Philadelphia, PA
Summary of Key Points (includes Editor’s Comments)
1. Dr. Stephan Willems advocated that asymptomatic A-Fib patients (30%-40% of A-Fib patients) should be treated with catheter ablation as soon as possible, rather than just leaving them in A-Fib.
Today’s Guidelines do not currently recommend this. …Continue reading my report> go to My Summary of All Five Talks.
More reports from the 2024 AF Symposium are coming the next few weeks.
